BACKGROUND AND OBJECTIVES: This retrospective study evaluated the feasibility and effectiveness of type II radical hysterectomies alone, or in combination with adjuvant treatment, for the treatment of patients with stage IB-IIB cervical cancer with or without high-risk factors. METHODS: A total of 960 stage IB-IIB patients who underwent type II radical hysterectomies between 1995 and 2004 were enrolled and retrospectively analyzed. RESULTS: Uterine corpus invasion, parametrial margin involvement, and pelvic lymph node metastasis were identified as independent prognostic factors for stage IB patients. For stage IIA-IIB patients, histologic type, parametrial margin involvement, and pelvic lymph node metastasis were identified as independent prognostic factors. The 5-year overall survival (OS) rates for patients with stage IB versus stage IIA-IIB cervical carcinomas were 88.4% and 78.5%, respectively. Moreover, adjuvant radiotherapy and chemotherapy improved the 5-year OS rates of stage IIA-IIB patients associated with high-risk factors. The overall recurrence rate for this cohort was 14.4%. CONCLUSIONS: Our findings show that type II radical hysterectomy is a feasible treatment option for stage IB-IIB cervical carcinoma patients. Furthermore, type II radical hysterectomy combined with adjuvant post-operative therapy improves the OS of women with high-risk factors for cervical carcinoma.
BACKGROUND AND OBJECTIVES: This retrospective study evaluated the feasibility and effectiveness of type II radical hysterectomies alone, or in combination with adjuvant treatment, for the treatment of patients with stage IB-IIB cervical cancer with or without high-risk factors. METHODS: A total of 960 stage IB-IIB patients who underwent type II radical hysterectomies between 1995 and 2004 were enrolled and retrospectively analyzed. RESULTS: Uterine corpus invasion, parametrial margin involvement, and pelvic lymph node metastasis were identified as independent prognostic factors for stage IB patients. For stage IIA-IIB patients, histologic type, parametrial margin involvement, and pelvic lymph node metastasis were identified as independent prognostic factors. The 5-year overall survival (OS) rates for patients with stage IB versus stage IIA-IIB cervical carcinomas were 88.4% and 78.5%, respectively. Moreover, adjuvant radiotherapy and chemotherapy improved the 5-year OS rates of stage IIA-IIB patients associated with high-risk factors. The overall recurrence rate for this cohort was 14.4%. CONCLUSIONS: Our findings show that type II radical hysterectomy is a feasible treatment option for stage IB-IIB cervical carcinomapatients. Furthermore, type II radical hysterectomy combined with adjuvant post-operative therapy improves the OS of women with high-risk factors for cervical carcinoma.
Authors: Emma R Allanson; Aime Powell; Max Bulsara; Hong Lim Lee; Lynette Denny; Yee Leung; Paul Cohen Journal: PLoS One Date: 2019-07-03 Impact factor: 3.240